Feb 3 2014;124(2):617-630
The discovery is exciting because it suggests appetite suppression may be possible without the gastrointestinal and muscle-loss costs of current GLP-1 agonists, but the human translation has not yet happened
2 Warhead Attenuation is Crucial: To widen this window, people cannot simply use highly potent standalone inhibitors as effector warheads
constipation, reflux, or intermittent nausea may continue Persistent or progressive symptoms rather than gradual improvement After month 3 Symptoms may remain mild or infrequent at a tolerated regimen New severe symptoms should not automatically be blamed on the medication The most important pattern is not simply "week 1 is bad and month 3 is good." A more accurate pattern is initiation, adaptation, possible symptom flare during dose escalation, and reassessment based on tolerability
Sold for research use only (RUO)
it has unleashed a massive generic wave that is actively reshaping India's metabolic healthcare landscape